Takeaways Health Canada’s approval of Novartis’ Vanrafia (atrasentan) creates Canada’s first endothelin receptor antagonist–based therapy specifically for IgA nephropathy, giving clini...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
